Merck & Co.
AWARDS
NEWS
The Wall Street Journal speculated today that it won’t be long before drug manufacturers start consolidating in order to improve their bottom lines.
The FDA accepted Merck & Co.’s supplemental Biologics License Application and granted Priority Review for Keytruda in advanced cervical cancer.
Biogen is buying Pfizer’s PF-04958242, a first-in-class, Phase IIb-ready drug to treat several neurological and psychiatric diseases, including schizophrenia.
Immutep Limited announced it will pair its lead immunotherapy product with Merck’s blockbuster PD-1 inhibitor Keytruda to treat three solid tumor types in a single trial.
Merck and Tokyo-based Eisai Co. have signed a strategic collaboration deal to develop and commercialize Lenvima with Merck’s anti-PD-1 drug Keytruda.
The U.S. Food and Drug Administration (FDA) issued new draft guidance for preclinical trials in Alzheimer’s.
JOBS
IN THE PRESS